Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Study ID
- NCT02437019
- Status
- Approved For Marketing
Conditions
- B-cell Chronic Lymphocytic Leukemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- PCI-32765 (Ibrutinib) — DRUGParticipants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
Study Details
The purpose of this study is to provide early access to Ibrutinib treatment for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and collect additional safety data while the medication is not commercially available.
Key Dates
- Status verified
- Mar 2017
Related Studies
- A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaPHASE3 · Recruiting · Grifols Therapeutics LLC · Huntington Park, California
- Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for LeukemiasPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland